Dexmedetomidine Combined with Target Controlled Infusion of Remifentanil for Medical Thoracoscopy: a Feasibility Study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300073623

Enrollment

Unknown

Registered

2023-07-17

Start date

2023-07-17

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases or conditions that require medical thoracoscopy under sedation

Interventions

experimental group:Dexmedetomidine combined with target controlled infusion of remifentanil

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1: Acception of elective medical thoracoscopy under sedation 2: American Society of Anesthesiologists (ASA) Classification I-III 3: Voluntary participation and comprehension of informed consent

Exclusion criteria

Exclusion criteria: 1: Inability to lie flat due to large pleural effusion 2: Difficult airway and severe respiratory disease 3: Coagulation disorders 4: Severe liver and kidney dysfunction 5: Severe cardiovascular and cerebrovascular diseases 6: Pregnancy 7: Long-term treatment with opioids, drug abuse or drug addiction

Design outcomes

Primary

Measure	Time frame
postoperative pain visual analogue scale;Incidence of intraoperative body movement;satisfaction of the operating physician;	—

Secondary

Measure	Time frame
Non-invasive blood pressure;Heart rate;Pulse oxygen saturation;Partial Pressure of Transcutaneous Carbon Dioxide;	—

Countries

China

Contacts

Public ContactBian Jinjun

Changhai Hospital, Naval Medical University

jinjunbicu@163.com+86 136 0196 3321

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026